ESR1 activating mutations: From structure to clinical application.

Abstract excerpt

Estrogen receptor-positive breast cancer is the most common type of both early and advanced breast cancer. Estrogen receptor alpha (ER) is a nuclear hormone receptor and a key driver of tumorigenesis and tumor progression in these breast cancers. As such, it is a key treatment target and a biomarker predictive of response to endocrine therapy. Activating ESR1 ligand binding domain mutations engender...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Receptors, Estrogen
• Share to Aromatase Inhibitors